Julie Delyon
Overview
Explore the profile of Julie Delyon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
519
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Delyon J, Becherirat S, Roger A, Bernard-Cacciarella M, Reger De Moura C, Louveau B, et al.
Cell Commun Signal
. 2024 Nov;
22(1):559.
PMID: 39574163
Background: Phosphodiesterase type 4D (PDE4D) breaks down cyclic AMP (cAMP) reducing the signaling of this intracellular second messenger which plays a major role in melanocyte pathophysiology. In advanced melanoma, expression...
2.
3.
Delyon J, Schmauch B, Jacob Y, Battistella M, Lebbe C
Eur J Cancer
. 2023 Oct;
195:113394.
PMID: 37891064
No abstract available.
4.
Delyon J, Vallet A, Bernard-Cacciarella M, Kuzniak I, Reger De Moura C, Louveau B, et al.
Cancers (Basel)
. 2023 Jun;
15(11).
PMID: 37296851
Because BRAF-mutated melanomas are addicted to the Mitogen Activated Protein Kinase (MAPK) pathway they show a high response rate to BRAF and MEK inhibitors. However, the clinical responses to these...
5.
El Zeinaty P, Lebbe C, Delyon J
Cancers (Basel)
. 2023 Feb;
15(3).
PMID: 36765830
Kaposi's sarcoma (KS) is a common neoplasm in Eastern and central Africa reflecting the spread of 8 (HHV-8), now considered a necessary causal agent for the development of KS. The...
6.
Cuendet M, Gatta R, Wicky A, Gerard C, Dalla-Vale M, Tavazzi E, et al.
Front Oncol
. 2022 Dec;
12:1043675.
PMID: 36568192
During the acute phase of the COVID-19 pandemic, hospitals faced a challenge to manage patients, especially those with other comorbidities and medical needs, such as cancer patients. Here, we use...
7.
Moghadam P, Herms F, Baroudjian B, Tetu P, Delyon J, Jouenne F, et al.
J Eur Acad Dermatol Venereol
. 2022 Aug;
37(1):e119-e121.
PMID: 35993817
No abstract available.
8.
Lebbe C, Biard L, Delyon J, Zuber J
Lancet Oncol
. 2022 Jul;
23(8):969-971.
PMID: 35809596
No abstract available.
9.
Rivas A, Delyon J, Martineau A, Blanc E, Allayous C, Meda L, et al.
Cancers (Basel)
. 2022 Jul;
14(13).
PMID: 35804963
Background: Immune checkpoint inhibitors (ICI) are currently the first-line treatment for patients with metastatic melanoma. We investigated the value of positron emission tomography (PET) response criteria to assess the therapeutic...
10.
Herms F, Baroudjian B, Delyon J, Laly P, Tetu P, Lebbe C, et al.
Acta Derm Venereol
. 2022 May;
102:adv00740.
PMID: 35604234
Sonidegib, a hedgehog pathway inhibitor, is indicated for treatment of locally advanced basal cell carcinoma, based on the results of the BOLT study. However, to date, no real-world study of...